The Sapigen Biologix vaccine plant, located in Odisha's Biotech Park in Andharua, is set to commence commercial production by May this year, marking a significant milestone as the state's inaugural vaccine manufacturing facility. With a projected capacity to produce 2.4 crore doses of various vaccines daily, officials anticipate it becoming the largest vaccine manufacturing plant in the country once fully operational.

According to a statement from the Chief Minister's Office (CMO), the facility is poised to manufacture over 15 vaccines targeting a range of diseases, including cholera and malaria. This development heralds a significant stride in bolstering healthcare infrastructure, not only in the state but also on a global scale.

The Rs 1,500-crore investment in the vaccine plant is expected to generate direct employment opportunities for 1,500 individuals, with a strong emphasis on recruiting local talent, as highlighted by the CMO. Furthermore, the diverse array of vaccines manufactured at the Bhubaneswar facility will be distributed to various regions worldwide, contributing to global health initiatives.

V K Pandian, Chairman of '5T' – a platform driving technology-led transformative initiatives – recently inspected the plant's sub-units and engaged with management and staff. He emphasized the importance of collaborative efforts from all government agencies to ensure the plant's timely commissioning within the next three months, underscoring the significance of this venture in advancing healthcare accessibility and innovation.